Stability of GLP-1 Analogues Under Various Storage Conditions
Key documentation to prepare: 6+ months of weight management records (dietitian visits, gym membership, food logs), lab work showing relevant biomarkers (A1C, lipid panel, blood pressure), a letter of medical necessity from your prescriber explaining why tirzepatide specifically is needed over alternatives, and any records of prior medication trials that were inadequate
however, individuals already taking glucose-lowering medicines (including insulin) may be at increased risk of hypoglycaemia if GH-mediated effects alter their insulin sensitivity Injection site reactions, including pain, redness, and infection risk For retatrutide , the side effect profile observed in clinical trials is consistent with that of other GLP-1 receptor agonists and includes nausea, vomiting, diarrhoea, and constipation
With over 11 million Canadians living with diabetes or prediabetes, and millions more affected by obesity, the potential impact is significant
